Vinati Organics Q2 FY27: PAT falls 32% YoY as margins compress despite 24% revenue growth

Vinati Organics' consolidated revenue rose 23.6% YoY to Rs680.21 Cr (Rs550.22 Cr a year ago) but was down 2.3% QoQ from Rs695.91 Cr in Q1 FY27. Consolidated PAT fell 31.8% YoY to Rs78.36 Cr (Rs114.88 Cr) and 28.0% QoQ (Rs108.86 Cr) — a clean operating decline with no exceptional items on either side of the comparison, so the raw and adjusted YoY PAT change are the same at -31.8%. Standalone told a similar story: PAT of Rs86.84 Cr (EPS Rs8.38) against consolidated PAT of Rs78.36 Cr (EPS Rs7.56), a roughly Rs8.5 Cr subsidiary-level drag this quarter. The entire story sits on the cost line, not revenue. Operating margin (EBITDA/revenue) compressed to 18.48% from 30.41% a year ago and 24.50% last quarter — a contraction of about 1,193 bps YoY and 602 bps QoQ — while net margin fell to roughly 11.5% of revenue from ~20.9% a year ago. Cost of materials consumed jumped to Rs404.22 Cr, or 59.4% of revenue, versus Rs263.68 Cr (47.9% of revenue) in the year-ago quarter, even as revenue grew strongly; input-cost pressure clearly outran both pricing and the revenue gain this quarter. The print missed Street: Prabhudas Lilladher's preview had modelled Q2 FY27 net sales of Rs609.8 Cr, EBITDA of Rs186.2 Cr and PAT of Rs127.6 Cr (+20.3% YoY). Actual revenue came in well above that (Rs680.2 Cr), but EBITDA (~Rs125.7 Cr) and PAT (Rs78.4 Cr) landed far short — the beat was entirely on the top line, and profitability missed by roughly a third. Against management's own guidance from the Q4 FY26 concall — ~15% FY27 volume growth and EBITDA margins held in the 26-27% range — the quarter's 23.6% YoY revenue growth clears the volume bar, but the 18.48% operating margin is nowhere close to the guided range, a clear miss on profitability guidance. The quarter's other disclosed corporate actions (a Rs9 Cr investment in a wholly owned subsidiary on Sep 21, trading-window closure ahead of results, BRSR/AGM filings in August) are governance and administrative in nature and do not explain the margin move; no management press release accompanied this filing to give a direct driver explanation. This sets up margin recovery as the key swing factor into H2 FY27, against management's own 26-27% EBITDA margin target and its guidance that new product revenue should start contributing from Q3 FY27 onward, alongside the Rs200-250 Cr FY27 capex plan.